Greg Levine Quoted in Institutional Investor Article on Biopharma Companies Facing Drug-Price Reckoning

In The News
October 9, 2015

Life sciences partner Greg Levine (Washington, D.C.) is quoted in an Institutional Investor (subscription required) article examining how biopharmaceutical companies are being forced to justify product value in the face of price gouging allegations in the specialty drug market. In the article, Greg discusses how drug makers are trying to communicate the value that new medicines deliver with educational messages, and the challenges of staging a rational debate in the current polarized environment.